Stay updated on Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The footer now identifies the site revision as v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-11-03T23:09:48.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    A general NIH notice about terminology changes appears above the blocked study page, and the site revision identifier changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T22:36:48.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T00:16:20.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    Key descriptors like the drug and diseases, plus associated indexing terms, were removed from the study record, and related metadata was reduced, which changes how the study is described and located within the platform.
    Difference
    17%
    Check dated 2026-09-22T23:40:01.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    Revision: v3.7.0 was added to the page footer, replacing Revision: v3.6.6. This indicates a version/template update for the study page.
    Difference
    0.1%
    Check dated 2026-09-15T23:42:52.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    Revision: v3.6.6 is now displayed on the page, replacing the previous v3.6.5. This reflects a routine update to the site's documentation or underlying components rather than a change to study content.
    Difference
    0.1%
    Check dated 2026-09-01T19:51:23.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page.